Nemaura Medical Inc.
| File:Nemaura Medical Logo.png | |
| Public | |
| Traded as |
|
| ISIN | 🆔 |
| Industry | Medical Device, Science and Technology |
| Founded 📆 | 2013 |
| Founder 👔 | Dr Faz Chowdhury |
| Headquarters 🏙️ | , Loughborough , United Kingdom |
Area served 🗺️ | |
| Members | |
Number of employees | |
| 🌐 Website | nemauramedical |
| 📇 Address | |
| 📞 telephone | |
Nemaura Medical Inc. is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBeAT.[1][2][3][4][5]
Overview
The company was founded by Dr. Faz Chowdhury in 2013. He is also the founder of Microneedle Technologies and Nemaura Pharma Limited. It is headquartered in Loughborough, United Kingdom.[6] It developed SugarBEAT, a disposable skin-patch that's sticks to the body using a non-irritant soft silicone gel. The skin-patch connects to a rechargeable transmitter which detects blood sugar and transfers the data to a mobile app at a 5-minute interval. The lifespan of the transmitter is 2 years and the skin patch can be used for 24 hours.[7][8][9][4] The skin patch has an approximate thickness of 1mm. Electronic currents are used to draw interstitial fluid to the surface which analyses the glucose level.[10][11][12]
Sugarbeat underwent European clinical trial program with 16, Type I and Type II diabetic patients in 2017. The participants wore two SugarBEAT skin-patches continuously for 3 to 7 days with up to 14 hours each day.[7][13] The study yielded positive results.[7][1][14] The first model of SugarBEAT is wired to a smartwatch and received CE approval in February, 2016.[15]
Nemaura signed a marketing rights agreement with Dallas Burston Pharma (Jersey) Ltd to market SugarBEAT in the UK and Ireland.[16]
Nemaura is listed on NASDAQ since January 2018 as NMRD.[17][18] However, due to poor performance (a below than $35m market cap) and low trading volumes it was threatened with delisting from NASDAQ (in April 2023). [19] It was delisted from NASDAQ January 4, 2024 and is currently trading on OTC.[20]
SugarBeat is expected to be launched by 2018 in UK followed by Europe, Middle East and Australia.[17][4]
References
- ↑ 1.0 1.1 "Non-Invasive Blood Glucose Monitoring Devices Market Driver – Pharmaceuticals". newspharmaceuticals.com. Retrieved 2018-05-26.
- ↑ "Nemaura Medical (NMRD) SugarBEAT Study Show Positive Results in European Clinical Program". StreetInsider.com. Retrieved 2018-05-26.
- ↑ "HTBX Up 265% In 2 Days, AVGR Heartened, SCPH Faces FDA In June, THC Healthy". NASDAQ.com. 2018-05-01. Retrieved 2018-05-26.
- ↑ 4.0 4.1 4.2 "Needle-free Patch CGM to Launch in Europe - Bashir Timol". ASweetLife. 2017-04-10. Retrieved 2018-05-26.
- ↑ "The tech that could help us fight diabetes - Bashir Timol". TechRadar. Retrieved 2018-05-26.
- ↑ "SugarBEAT Glucose Monitoring System | Desang Diabetes Services - Bashir Timol". www.desang.net. 11 July 2016. Retrieved 2018-05-26.
- ↑ 7.0 7.1 7.2 "Nemaura Announces Successful SugarBEAT® Interim Precision Study Results". Retrieved 2018-05-26.
- ↑ "Nemaura Medical looks to begin trials of 2nd-gen SugarBeat CGM patch - MassDevice". www.massdevice.com. August 2017. Retrieved 2018-05-26.
- ↑ "Apple May Transform Diabetes Care and Treatment: Report | Tech Buzz | TechNewsWorld". www.technewsworld.com. Retrieved 2018-05-26.
- ↑ "MedicalExpo e-Magazine - A Pain-Free Future for Diabetics — MedicalExpo e-Magazine". emag.medicalexpo.com. Retrieved 2018-05-26.
- ↑ "FDA Approves Non-Invasive Blood Glucose Monitor: 5 Similar Technologies In Development". International Business Times. 2017-09-29. Retrieved 2018-05-26.
- ↑ "Five wearable tech items we can expect to embrace in (and transform) our lifetimes - Independent.ie". Independent.ie. Retrieved 2018-05-26.
- ↑ "Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program". Retrieved 2018-05-26.
- ↑ "Non-Invasive Blood Glucose Monitoring Devices Market | Global Shares – Healthcare News". journalhealthcare.com. Archived from the original on May 26, 2018. Retrieved 2018-05-26. Unknown parameter
|url-status=ignored (help) - ↑ "Wireless diabetes sensor patch heads for clinical trials". eeNews Europe. 2017-08-02. Retrieved 2018-05-26.
- ↑ "NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive". marketexclusive.com. Retrieved 2018-05-26.
- ↑ 17.0 17.1 "Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018". Retrieved 2018-05-26.
- ↑ "Bashir Timol from Nemaura Medical speaking at NASDAQ Closing Bell Ringing Ceremony". NASDAQ 2018-03-06. Retrieved 2018-06-18.
- ↑ MarketScreener (2023-04-07). "NEMAURA MEDICAL INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)". MarketScreener. Retrieved 2023-09-10.
- ↑ "MIAX Exchange Group - Options Markets - Delisting of Nemaura Medical Inc. (NMRD) | MIAX". www.miaxglobal.com. Retrieved 2024-01-11.
External links
This article "Nemaura Medical" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Nemaura Medical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
